Pharma R&D Shifts: Trouble for Global South
- Okay, here's a breakdown of the main arguments and concerns presented in the text, organized for clarity.I'll cover the core problem, the contributing factors, the consequences, and potential...
- The author argues that a growing "innovation gap" - possibly becoming an "innovation chasm" - threatens the development of new medicines for neglected infectious diseases that disproportionately affect...
- * Increased Costs for Non-Profits: Non-profit R&D organizations will need to build internal expertise, making their work more expensive and potentially distancing them from private sector innovation.
Okay, here’s a breakdown of the main arguments and concerns presented in the text, organized for clarity.I’ll cover the core problem, the contributing factors, the consequences, and potential (though limited) solutions.
Core Problem:
The author argues that a growing “innovation gap” – possibly becoming an ”innovation chasm” – threatens the development of new medicines for neglected infectious diseases that disproportionately affect the world’s poorest populations. The traditional sources of innovation are drying up,and while new sources are emerging,thay aren’t developing quickly enough to meet the urgent need.
Contributing Factors (why the Innovation is Drying Up):
- Big Pharma Shift in Focus: Large pharmaceutical companies are increasingly:
* Outsourcing R&D: Relying on contract research organizations (CROs) and contract manufacturing organizations (CMOs), leading to a loss of in-house expertise that non-profit R&D organizations previously benefited from through in-kind donations.* In-Licensing Blockbusters: Preferring to acquire already-developed technologies with high commercial potential (“blockbusters”) rather than investing in early-stage research for neglected diseases.
* focusing on High-Cost Therapies: Concentrating internal R&D on expensive, personalized medicine modalities like biologics, mRNA, and gene therapies. These are often inaccessible to those who need them most (e.g., sickle cell gene therapy costing over $1 million, while 80% of sickle cell cases are in sub-Saharan Africa).
- Biotech Challenges: Biotech companies, while potentially innovative, frequently enough struggle with funding and are unable to partner effectively with non-profits or navigate the complex path to market authorization and commercialization for these diseases.
- Reduced Funding: Cuts to foreign aid and early-stage research exacerbate the problem.
Consequences:
* Increased Costs for Non-Profits: Non-profit R&D organizations will need to build internal expertise, making their work more expensive and potentially distancing them from private sector innovation.
* Worsening Neglected Disease Burden: Over 1 billion people are affected by neglected tropical diseases annually, and the lack of innovation will leave them without the medicines they desperately need.
* A Widening Gap: The gap between the diseases affecting the poorest and the innovation directed towards them will continue to grow.
* Focus on Access vs. Creation: Discussions around access to medicines (technology transfer,local production) are significant,but the author emphasizes the prior need to address where the technologies will come from in the first place.
Emerging Solutions/Shifting Landscape (But with Caveats):
* Rise of Academic Research: Universities are stepping up in drug discovery and development, filling some of the void left by big pharma.
* Innovation in Low- and Middle-Income Countries (LMICs): Countries like brazil, India, and China are becoming significant sources of medical innovation, especially in vaccines and diagnostics. Research is also growing in endemic countries like South Africa, Brazil, and Thailand. (The author’s institution is partnering with the Serum Institute of India on a dengue treatment.)
* However: the author cautions that not all LMICs have the same research capacity, and it will take time for them to reach the scale needed to address all neglected infectious diseases. “We don’t have that time.”
In essence, the author is sounding an alarm about a systemic shift in the pharmaceutical industry that is leaving the world’s most vulnerable populations behind. While acknowledging emerging innovation hubs, they stress the urgency of the situation and the need for a more robust and lasting innovation model for neglected infectious diseases.
Let me know if you’d like me to elaborate on any specific aspect of this analysis!